CVS Pharmacology: ACE Inhibitors, Angiotensin Receptor Blockers, and the RAAS Pathway

Introduction / Overview

Hypertension and heart failure remain leading causes of morbidity and mortality worldwide. The renin–angiotensin–aldosterone system (RAAS) is a central regulator of systemic vascular resistance and fluid homeostasis. Modulation of RAAS activity has become a cornerstone of cardiovascular therapy, with two major pharmacologic classes—angiotensin‑converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs)—providing durable benefits across a spectrum of cardiovascular conditions. Understanding the biochemical underpinnings, clinical applications, and safety profiles of these agents is essential for clinicians and pharmacists engaged in the management of cardiovascular disease.

Learning Objectives

• Describe the structure, function, and regulation of the RAAS.
• Explain the pharmacodynamic mechanisms of ACE inhibitors and ARBs.
• Outline the pharmacokinetic properties that influence dosing and therapeutic monitoring.
• Identify approved indications and common off‑label uses of ACE inhibitors and ARBs.
• Recognize major adverse effects, drug interactions, and special population considerations.

Classification

Drug Classes and Categories

ACE inhibitors and ARBs are both targeted at components of the RAAS but operate via distinct mechanisms. ACE inhibitors block the enzymatic conversion of angiotensin I to angiotensin II, whereas ARBs competitively inhibit the angiotensin II type 1 (AT₁) receptor. Both classes are often grouped under antihypertensive agents; however, their molecular actions warrant separate consideration.

Chemical Classification

ACE inhibitors are generally classified according to their backbone structure: phenylpropyl carboxylic acids (e.g., enalapril), imidazolidinone derivatives (e.g., lisinopril), and dicarboxylic acids (e.g., captopril). ARBs are composed of a biphenyl‑alkyl–piperazine scaffold, with structural variations that influence receptor affinity and pharmacokinetics. The chemical diversity within each class contributes to differences in half‑life, bioavailability, and side‑effect profiles.

Mechanism of Action

Detailed Pharmacodynamics

The RAAS initiates with the release of renin from juxtaglomerular cells, converting angiotensinogen to angiotensin I. ACE, predominantly located on pulmonary capillary endothelium, catalyzes the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor and stimulator of aldosterone secretion. ACE also degrades bradykinin, a vasodilatory peptide. ACE inhibitors inhibit this catalytic step, resulting in reduced angiotensin II synthesis and increased bradykinin levels. Consequently, systemic vascular resistance decreases, sodium excretion increases, and sympathetic tone is attenuated.

ARBs block the AT₁ receptor, preventing angiotensin II from eliciting vasoconstriction, aldosterone release, and pro‑inflammatory signaling. Unlike ACE inhibitors, ARBs do not influence bradykinin metabolism; therefore, the incidence of cough is generally lower. Both drug classes ultimately lower blood pressure and improve cardiac remodeling, yet their molecular footprints differ, influencing tolerability and drug interactions.

Receptor Interactions

ACE inhibitors indirectly reduce activation of AT₁ receptors by lowering angiotensin II concentrations, whereas ARBs directly antagonize AT₁ receptors. ARBs may lead to increased circulating angiotensin II, which can then activate the less‑studied angiotensin II type 2 (AT₂) receptor, potentially mediating vasodilatory and anti‑fibrotic effects. The balance between these receptor pathways may partially explain differences in clinical outcomes observed in head‑to‑head trials.

Molecular / Cellular Mechanisms

At the cellular level, decreased angiotensin II signaling translates to reduced intracellular calcium influx in vascular smooth muscle cells, leading to vasodilation. In cardiomyocytes, inhibition of AT₁ receptor activity attenuates hypertrophic gene expression, thereby slowing pathological remodeling. Both ACE inhibitors and ARBs also modulate the production of reactive oxygen species and inflammatory cytokines, contributing to their organ‑protective effects beyond blood pressure control.

Pharmacokinetics

Absorption

ACE inhibitors are typically administered orally, with variable bioavailability. Lisinopril and enalapril exhibit high oral absorption, whereas captopril has lower bioavailability due to first‑pass metabolism. ARBs generally have excellent absorption profiles; valsartan and losartan, for example, reach peak plasma concentrations within 2–3 hours post‑dose. Food intake may delay absorption for certain agents but rarely alters overall exposure.

Distribution

Both drug classes exhibit extensive distribution into peripheral tissues. ACE inhibitors possess high plasma protein binding rates (typically >90%), whereas ARBs show moderate binding (70–90%). Tissue penetration allows for effective blockade of angiotensin II synthesis or receptor activity in the heart, kidneys, and vasculature.

Metabolism

ACE inhibitors undergo hepatic metabolism to active or inactive metabolites. Enalapril is hydrolyzed to its active form, enalaprilat; lisinopril is excreted unchanged. ARBs are metabolized variably: losartan is metabolized to an active metabolite (losartan carboxylate), while valsartan is largely excreted unchanged. The metabolic pathways influence drug‑drug interaction potential, particularly with agents that inhibit or induce cytochrome P450 enzymes.

Excretion

Renal excretion predominates for both classes. ACE inhibitors are eliminated via glomerular filtration and tubular secretion, necessitating dose adjustment in renal impairment. ARBs are also cleared renally; however, some agents (e.g., losartan) have significant hepatic metabolism, allowing for alternative elimination routes. The half‑lives range from 12 to 24 hours for ACE inhibitors and 6 to 20 hours for ARBs, permitting once‑daily dosing in most therapeutic contexts.

Half‑Life and Dosing Considerations

Given the variability in pharmacokinetics, individual agents are prescribed based on patient characteristics, co‑morbidities, and concurrent medications. Initiation at lower doses with gradual uptitration is common practice to minimize adverse events. Therapeutic drug monitoring is usually unnecessary; however, serum creatinine and potassium should be monitored when therapy is initiated or intensified.

Therapeutic Uses / Clinical Applications

Approved Indications

ACE inhibitors are indicated for essential hypertension, heart failure with reduced ejection fraction, post‑myocardial infarction left ventricular remodeling, and diabetic nephropathy. ARBs share a similar indication profile, with preferential use in patients intolerant to ACE inhibitors. Both drug classes are also employed in the management of resistant hypertension, chronic kidney disease, and aortic aneurysm surveillance.

Off‑Label Uses

Evidence suggests benefits of ACE inhibitors in pulmonary arterial hypertension and in mitigating chemotherapy‑induced cardiotoxicity. ARBs are increasingly used for neuroprotection in patients with ischemic stroke and for non‑cardiovascular indications such as osteoarthritis pain modulation, although formal approval is lacking. Their anti‑inflammatory properties may also provide adjunctive benefit in certain autoimmune disorders.

Adverse Effects

Common Side Effects

Hypertension can paradoxically cause a transient rise in blood pressure upon initiation. ACE inhibitors frequently cause a dry cough due to bradykinin accumulation; the incidence is dose‑dependent and higher among East Asian populations. Hypotension, dizziness, and syncope may occur, particularly in volume‑depleted states. ARBs are generally well tolerated, with headache and dizziness as the most frequent complaints.

Serious / Rare Adverse Reactions

A persistent cough may necessitate discontinuation. Angioedema, though rare (<0.1% of users), represents a potentially life‑threatening allergic reaction; prompt cessation is advised. Hyperkalemia is a concern, especially when combined with potassium‑sparing diuretics, ACE inhibitors, or ARBs. Renal dysfunction may develop due to intrarenal vasoconstriction in patients with bilateral renal artery stenosis.

Black Box Warnings

Both drug classes carry warnings for the use during the second and third trimesters of pregnancy, as teratogenic effects on the fetal renal system have been documented. Additionally, ACE inhibitors and ARBs are contraindicated in patients with a history of angioedema precipitated by prior ACE inhibitor therapy.

Drug Interactions

Major Drug-Drug Interactions

Concurrent use with potassium‑sparing diuretics, potassium supplements, or sodium‑glucose cotransporter‑2 inhibitors may precipitate hyperkalemia. Non‑steroidal anti‑inflammatory drugs (NSAIDs) can blunt the antihypertensive effect and impair renal function due to reduced prostaglandin‑mediated vasodilation. ACE inhibitors are metabolized by cytochrome P450 2C9; thus, inhibitors or inducers of this enzyme (e.g., amiodarone, rifampin) may alter drug levels.

Contraindications

Patients with a history of ACE inhibitor‑related angioedema, severe renal artery stenosis, or those on lithium therapy should avoid ACE inhibitors due to increased lithium levels. ARBs are contraindicated in patients with a history of hypersensitivity to the drug or its excipients. Both classes are contraindicated in pregnancy and during the lactation period.

Special Considerations

Use in Pregnancy / Lactation

Evidence indicates that ACE inhibitors and ARBs are associated with fetal renal dysgenesis and oligohydramnios. Consequently, these agents are contraindicated from the second trimester onward. During lactation, the concentration of these drugs in breast milk is low, but clinical caution is advised given the potential for neonatal hypotension.

Pediatric / Geriatric Considerations

In pediatric populations, dosing is weight‑based; however, long‑term safety data are limited. Geriatric patients often exhibit reduced renal clearance; thus, dose adjustments based on creatinine clearance are recommended. Awareness of age‑related changes in pharmacodynamics, such as increased sensitivity to hypotension, is essential.

Renal / Hepatic Impairment

ACE inhibitors require dose reduction in patients with estimated glomerular filtration rates below 30 mL/min/1.73 m², and therapy is usually avoided in end‑stage renal disease. ARBs may be used with caution in hepatic impairment due to altered metabolism; nonetheless, renally excreted drugs may accumulate. Clinical monitoring of serum creatinine and potassium should be intensified in these populations.

Summary / Key Points

• The RAAS is a pivotal regulator of cardiovascular homeostasis, and its modulation provides therapeutic benefit in multiple conditions.
• ACE inhibitors block angiotensin II formation and increase bradykinin, whereas ARBs block AT₁ receptors, yielding distinct tolerability profiles.
• Both drug classes are first‑line agents for hypertension, heart failure, and diabetic nephropathy, with careful dose titration to mitigate adverse events.
• Hyperkalemia, renal dysfunction, and angioedema are the primary safety concerns; monitoring is advised in susceptible populations.
• Drug interactions, particularly with potassium‑sparing agents and NSAIDs, can compromise efficacy or safety; vigilant medication reconciliation is warranted.

Clinical decision‑making should incorporate patient‑specific factors such as comorbidities, potential drug interactions, and the risk–benefit profile of each class. Ongoing research continues to refine the optimal use of ACE inhibitors and ARBs within the evolving landscape of cardiovascular therapeutics.

References

1. Opie LH, Gersh BJ. Drugs for the Heart. 9th ed. Philadelphia: Elsevier; 2021.
2. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
3. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
4. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
5. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
6. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
7. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.